Company profile
ANNOVIS BIO, INC.
NYSE:ANVSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BUNTANETAP | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05686044 | phase2_3 | completed | 2023-04-01 | 2024-02-13 | Annovis Bio Inc. | A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD |
| NCT06709014 | phase3 | active_not_recruiting | 2025-02-04 | 2027-12-01 | Annovis Bio Inc. | A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD |
| NCT05357989 | phase3 | completed | 2022-08-03 | 2023-12-04 | Annovis Bio Inc. | A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
| NCT07284784 | phase2_3 | recruiting | 2026-01-09 | 2029-09-01 | Annovis Bio Inc. | A Study of Buntanetap in Participants With PD |
| NCT07757204 | phase2_3 | not_yet_recruiting | 2026-09-21 | 2030-02-21 | Annovis Bio Inc. | An Open-label Long-term Safety Study of Buntanetap in Participants With AD |
FDA applications (0)
No records yet.